Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G6TL
|
|||
| Former ID |
DIB016558
|
|||
| Drug Name |
DiaPep-277
|
|||
| Synonyms |
Diaccine; AVE-0277; AVE-277; Antidiabetic, Peptor
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 3 | [1] | |
| Company |
Andromeda biotech
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C106H180N28O34
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)N2CCCC2C(=O)NC(C)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(C(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)N
|
|||
| InChI |
1S/C106H180N28O34/c1-23-55(18)83(131-102(164)82(54(16)17)130-90(152)60(27-24-32-111-106(109)110)118-91(153)65(38-50(8)9)123-92(154)63(36-48(4)5)121-87(149)58(21)117-101(163)81(53(14)15)129-76(140)45-113-74(138)43-112-75(139)44-114-88(150)62(35-47(2)3)126-100(162)80(108)52(12)13)103(165)133-33-25-28-71(133)98(160)115-56(19)85(147)120-64(37-49(6)7)93(155)125-68(41-78(143)144)95(157)128-70(46-135)97(159)124-66(39-51(10)11)96(158)132-84(59(22)136)104(166)134-34-26-29-72(134)99(161)116-57(20)86(148)122-67(40-73(107)137)94(156)119-61(30-31-77(141)142)89(151)127-69(105(167)168)42-79(145)146/h47-72,80-84,135-136H,23-46,108H2,1-22H3,(H2,107,137)(H,112,139)(H,113,138)(H,114,150)(H,115,160)(H,116,161)(H,117,163)(H,118,153)(H,119,156)(H,120,147)(H,121,149)(H,122,148)(H,123,154)(H,124,159)(H,125,155)(H,126,162)(H,127,151)(H,128,157)(H,129,140)(H,130,152)(H,131,164)(H,132,158)(H,141,142)(H,143,144)(H,145,146)(H,167,168)(H4,109,110,111)/t55-,56-,57-,58-,59+,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,80-,81-,82-,83-,84-/m0/s1
|
|||
| InChIKey |
VGGRNGOEDNBLPH-YJHCMWSWSA-N
|
|||
| CAS Number |
CAS 179822-83-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mitochondrial matrix protein P1 (HSPD1) | Target Info | Modulator | [2], [3] |
| KEGG Pathway | RNA degradation | |||
| Type I diabetes mellitus | ||||
| Legionellosis | ||||
| Tuberculosis | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| Endogenous TLR signaling | ||||
| Reactome | Mitochondrial protein import | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01460251) OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277. U.S. National Institutes of Health. | |||
| REF 2 | Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev. 2007 May;23(4):269-75. | |||
| REF 3 | Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev. 2009 May;25(4):316-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.